NAFLD1
MCID: FTT008
MIFTS: 60

Fatty Liver Disease, Nonalcoholic 1 (NAFLD1)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 57 29
Hepatic Steatosis 75 29 6
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 57 13
Nafld1 57 75
Non-Alcoholic Fatty Liver Disease 1 75
Steatohepatitis 73
Fatty Liver 73

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

32
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 57 613282
MeSH 44 D005234
SNOMED-CT via HPO 69 197321007 442191002

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 57 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipodystrophy, familial partial, type 2 and chylomicron retention disease. An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Developmental Biology and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. Affiliated tissues include liver, testes and heart, and related phenotypes are hepatic steatosis and growth/size/body region

UniProtKB/Swiss-Prot : 75 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 31.9 INS LEP
2 chylomicron retention disease 31.7 FABP1 MTTP
3 lipodystrophy, congenital generalized, type 1 31.6 ADIPOQ INS LEP
4 fatty liver disease 31.6 ADIPOQ INS LEP PPARA SLC17A5 SREBF1
5 hepatitis 31.3 GPT KRT18 SLC17A5
6 hyperglycemia 30.4 ADIPOQ INS LEP
7 liver disease 30.3 ADIPOQ GPT INS KRT18 LEP PPARA
8 glucose intolerance 30.1 ADIPOQ INS LEP RETN
9 nonalcoholic steatohepatitis 30.1 ADIPOQ GPT INS KRT18 LEP SLC17A5
10 viral hepatitis 30.1 GPT KRT18 SLC17A5
11 nonalcoholic fatty liver disease 30.0 ADIPOQ INS KRT18 LEP MTTP NAFLD1
12 kwashiorkor 30.0 GPT SLC17A5
13 atherosclerosis susceptibility 29.9 ADIPOQ INS PPARA
14 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 29.9 ADIPOQ INS
15 arteries, anomalies of 29.6 ADIPOQ INS LEP
16 acanthosis nigricans 29.5 ADIPOQ INS LEP PRMT7
17 chronic kidney failure 29.5 ADIPOQ INS LEP
18 lipid metabolism disorder 29.3 ADIPOQ INS LEP MTTP PPARA RETN
19 morbid obesity 29.2 ADIPOQ INS LEP RETN
20 gestational diabetes 29.2 ADIPOQ INS LEP RETN
21 diabetes mellitus 29.2 ADIPOQ INS LEP PPARA RETN
22 liver cirrhosis 28.9 ADIPOQ GPT KRT18 LEP RETN SLC17A5
23 overnutrition 28.7 ADIPOQ INS LEP PPARA RETN SREBF1
24 body mass index quantitative trait locus 11 28.5 ADIPOQ GPT INS LEP MTTP PPARA
25 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.2
26 abetalipoproteinemia 11.5
27 citrullinemia, type ii, adult-onset 11.5
28 hypobetalipoproteinemia, familial, 1 11.5
29 lipodystrophy, congenital generalized, type 2 11.3
30 lipodystrophy, congenital generalized, type 3 11.3
31 lipodystrophy, familial partial, type 6 11.3
32 visceral steatosis 11.2
33 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 11.2
34 adrenomyodystrophy 11.1
35 mitochondrial trifunctional protein deficiency 11.1
36 3-methylglutaconic aciduria, type v 11.1
37 neutral lipid storage disease with myopathy 11.1
38 lipodystrophy, congenital generalized, type 4 11.1
39 lipodystrophy, familial partial, type 5 11.1
40 muscular dystrophy, limb-girdle, autosomal recessive 18 11.1
41 combined oxidative phosphorylation deficiency 16 11.1
42 combined oxidative phosphorylation deficiency 21 11.1
43 hepatitis c 10.6
44 hepatitis b 10.6
45 hepatitis c virus 10.4
46 fish-eye disease 10.3
47 viral infectious disease 10.2
48 hepatocellular carcinoma 10.2
49 paraquat poisoning 10.2 GPT SLC17A5
50 pyridoxine deficiency 10.2 GPT SLC17A5

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Symptoms via clinical synopsis from OMIM:

57
Abdomen Liver:
fatty liver (hepatic steatosis), nonalcoholic


Clinical features from OMIM:

613282

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

32
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 32 HP:0001397

MGI Mouse Phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.81 ADIPOQ HADHA INS KRT18 LEP MTTP
2 homeostasis/metabolism MP:0005376 9.7 ADIPOQ FABP1 HADHA INS LEP MTTP
3 adipose tissue MP:0005375 9.65 ADIPOQ INS LEP PPARA RETN
4 liver/biliary system MP:0005370 9.36 ADIPOQ FABP1 HADHA INS KRT18 LEP

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Search Clinical Trials , NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

# Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 29
2 Hepatic Steatosis 29

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

41
Liver, Testes, Heart, Endothelial, Ovary, Kidney, Breast

Publications for Fatty Liver Disease, Nonalcoholic 1

Articles related to Fatty Liver Disease, Nonalcoholic 1:

(show top 50) (show all 1231)
# Title Authors Year
1
Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on Pparα promoter. ( 30404040 )
2019
2
6-gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. ( 30408433 )
2019
3
Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. ( 29719598 )
2018
4
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
5
Choline Supplementation Prevents a Hallmark Disturbance of Kwashiorkor in Weanling Mice Fed a Maize Vegetable Diet: Hepatic Steatosis of Undernutrition. ( 29786674 )
2018
6
Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. ( 29974410 )
2018
7
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model. ( 29975946 )
2018
8
Dihydrocapsiate supplementation prevented high-fat diet-induced adiposity, hepatic steatosis, glucose intolerance, and gut morphological alterations in mice. ( 29673543 )
2018
9
Epigenetic programming at the Mogat1 locus may link neonatal overnutrition with long-term hepatic steatosis and insulin resistance. ( 29812971 )
2018
10
Physical activity and Mediterranean diet based on olive tree phenolic compounds from two different geographical areas have protective effects on early osteoarthritis, muscle atrophy and hepatic steatosis. ( 29450729 )
2018
11
Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. ( 30509601 )
2018
12
Hepatic Steatosis is Prevalent following Orthotopic Liver Transplantation in Children with Cystic Fibrosis. ( 30234762 )
2018
13
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. ( 29399276 )
2018
14
Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015. ( 30310098 )
2018
15
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. ( 30178600 )
2018
16
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. ( 30059671 )
2018
17
Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. ( 30074820 )
2018
18
The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. ( 30098126 )
2018
19
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. ( 29924135 )
2018
20
Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. ( 29749323 )
2018
21
The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet. ( 29850450 )
2018
22
Recipient But Not Donor Adiponectin Polymorphisms Are Associated With Early Posttransplant Hepatic Steatosis in Patients Transplanted for Non-Nonalcoholic Fatty Liver Disease Indications. ( 29863454 )
2018
23
Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease. ( 29509992 )
2018
24
Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver. ( 29512720 )
2018
25
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. ( 29551054 )
2018
26
MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. ( 29561981 )
2018
27
Botryosphaeran reduces obesity, hepatic steatosis, dyslipidaemia, insulin resistance and glucose intolerance in diet-induced obese rats. ( 30227131 )
2018
28
Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats. ( 28142230 )
2018
29
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. ( 30419649 )
2018
30
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. ( 30360031 )
2018
31
Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients. ( 30229840 )
2018
32
Black Soybean Leaf Extract Suppresses Hyperglycemia and Hepatic Steatosis by Enhancing Adiponectin Receptor Signaling and AMPK Activation. ( 30541285 )
2018
33
Oxidative stress on ischemia/reperfusion injury in mice with non-alcoholic hepatic steatosis or steatohepatitis. ( 30328907 )
2018
34
The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. ( 30077415 )
2018
35
Do Zones of Hepatic Steatosis Associate With Subtypes and Progression of Nonalcoholic Fatty Liver Disease in Children? ( 29199148 )
2018
36
Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice. ( 30556037 )
2018
37
Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis. ( 30094399 )
2018
38
Salusin-α attenuates hepatic steatosis and atherosclerosis in high fat diet-fed low density lipoprotein receptor deficient mice. ( 29704496 )
2018
39
Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. ( 29400692 )
2018
40
Dietary methionine restriction reduces hepatic steatosis and oxidative stress in high-fat-fed mice by promoting H2S production. ( 30534793 )
2018
41
α-Linolenic acid prevents hepatic steatosis and improves glucose tolerance in mice fed a high-fat diet. ( 30379219 )
2018
42
Histopathological changes and onset of severe hepatic steatosis in rats fed a choline-free diet. ( 30186395 )
2018
43
Hesperidin and capsaicin, but not the combination, prevent hepatic steatosis and other metabolic syndrome-related alterations in western diet-fed rats. ( 30305645 )
2018
44
Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice. ( 29979770 )
2018
45
Açai (Euterpe oleracea Mart.) seed flour prevents obesity-induced hepatic steatosis regulating lipid metabolism by increasing cholesterol excretion in high-fat diet-fed mice. ( 30007703 )
2018
46
20-Week follow-up of hepatic steatosis installation and liver mitochondrial structure and activity and their interrelation in rats fed a high-fat-high-fructose diet. ( 29498345 )
2018
47
Apoptosis during the development of the hepatic steatosis in force-fed ducks and cooking yield implications. ( 29509948 )
2018
48
Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice. ( 29428667 )
2018
49
PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. ( 30189691 )
2018
50
DS-7250, a Diacylglycerol Acyltransferase 1 Inhibitor, Enhances Hepatic Steatosis in Zucker Fatty Rats via Upregulation of Fatty Acid Synthesis. ( 29587622 )
2018

Variations for Fatty Liver Disease, Nonalcoholic 1

ClinVar genetic disease variations for Fatty Liver Disease, Nonalcoholic 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OPA1 NM_015560.2(OPA1): c.113_130del18 (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 GRCh38 Chromosome 3, 193614803: 193614820
2 OPA1 NM_015560.2(OPA1): c.113_130del18 (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 GRCh37 Chromosome 3, 193332592: 193332609
3 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
4 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275
5 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic rs1014959895 GRCh37 Chromosome 16, 68363008: 68363008
6 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic rs1014959895 GRCh38 Chromosome 16, 68329105: 68329105
7 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 16, 68389688: 68389688
8 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 16, 68355785: 68355785

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

Pathways related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 ADIPOQ INS KRT18 LEP PPARA SREBF1
2
Show member pathways
12.51 ADIPOQ INS LEP RETN
3
Show member pathways
12.41 ADIPOQ FABP1 HADHA LEP PPARA SREBF1
4 12.2 ADIPOQ FABP1 INS SREBF1
5
Show member pathways
12.08 ADIPOQ INS LEP SREBF1
7
Show member pathways
11.65 INS PPARA SREBF1
8 11.37 ADIPOQ FABP1 PPARA
9 11.27 ADIPOQ LEP PPARA
10 11.22 ADIPOQ INS LEP PPARA RETN SREBF1
11 10.94 FABP1 PPARA
12 10.91 ADIPOQ LEP
13 10.84 ADIPOQ LEP
14 10.76 PPARA SREBF1
15 10.66 GPT INS

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Biological processes related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 ADIPOQ INS LEP RETN
2 response to hypoxia GO:0001666 9.76 ADIPOQ LEP PPARA
3 lipid metabolic process GO:0006629 9.72 HADHA LEP MTTP PPARA SREBF1
4 glucose homeostasis GO:0042593 9.69 ADIPOQ INS LEP
5 positive regulation of glucose import GO:0046326 9.6 ADIPOQ INS
6 negative regulation of blood pressure GO:0045776 9.59 ADIPOQ PPARA
7 lipoprotein metabolic process GO:0042157 9.57 MTTP PPARA
8 response to lipid GO:0033993 9.56 PPARA SREBF1
9 positive regulation of cellular protein metabolic process GO:0032270 9.55 ADIPOQ INS
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.54 INS LEP
11 negative regulation of gluconeogenesis GO:0045721 9.52 ADIPOQ INS
12 intestinal absorption GO:0050892 9.49 FABP1 LEP
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.48 ADIPOQ PPARA
14 positive regulation of fatty acid beta-oxidation GO:0032000 9.46 FABP1 PPARA
15 negative regulation of appetite GO:0032099 9.43 LEP PPARA
16 glucose metabolic process GO:0006006 9.43 ADIPOQ INS LEP
17 negative regulation of feeding behavior GO:2000252 9.4 INS RETN
18 regulation of fatty acid metabolic process GO:0019217 9.37 PPARA SREBF1
19 fatty acid beta-oxidation GO:0006635 9.33 ADIPOQ HADHA LEP
20 circadian rhythm GO:0007623 9.26 ADIPOQ LEP MTTP SREBF1
21 response to insulin GO:0032868 8.92 HADHA LEP PPARA RETN

Molecular functions related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 8.96 FABP1 PPARA
2 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....